Cravath, Swaine & Moore LLP has advised DRI Healthcare Trust. Ropes & Gray LLP has advised Bain Capital. DRI Healthcare Trust (TSX: DHT:UN) (TSX: DHT:U) has...
DRI Healthcare to Acquire Tavapadon Royalty Rights for US$316 Million
Teva Announces Proposed Acquisition of BioXcel Neuroscience Asset in Court-Supervised Sale
Ropes & Gray has advised Teva Pharmaceuticals. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced its proposed acquisition of certain neuroscience assets from BioXcel Therapeutics, Inc....
Tanabe Pharma Sells Global Rights to Oral Therapy Dersimelagon to LEO Pharma
Ropes & Gray LLP has advised Tanabe Pharma Corporation in its agreement with LEO Pharma. Tanabe Pharma Corporation has announced the transfer of all global development...
Mirador Therapeutics Secures Exclusive Worldwide License for Anti-C5a Antibody KP-301 from Kira Pharmaceuticals
Ropes & Gray has advised Mirador Therapeutics in its exclusive worldwide license agreement with Kira Pharmaceuticals. Mirador Therapeutics, Inc., a clinical-stage precision medicine company, has entered...
Sanofi and EVOQ Therapeutics Sign $500 Million Collaboration and Licensing Agreement
Ropes & Gray has advised Sanofi. Sanofi has entered into a collaboration and global license agreement with EVOQ Therapeutics to develop therapies for autoimmune diseases using...
Bristol Myers Squibb and Bain Capital Establish Biopharmaceutical Company Focused on Immunology Therapies
Ropes & Gray has advised Bain Capital on the deal. Bristol Myers Squibb and Bain Capital have announced the creation of a new independent biopharmaceutical company...
Sanofi Invests up to $25 Million in Adagene SAFEbody Antibody Program
Ropes & Gray has advised Sanofi. Davis Polk & Wardwell and Walkers (Hong Kong) have advised Adagene Inc. Sanofi has announced a strategic investment of up...
AbbVie Acquires Capstan Therapeutics in $2.1 Billion Deal to Expand Immunotherapy Portfolio
Ropes & Gray has advised AbbVie on the transaction, and Cooley has advised Capstan Therapeutics AbbVie has announced the acquisition of Capstan Therapeutics in a transaction...
Prilenia Therapeutics’ Licensing Agreement with Ferrer Internacional
Ropes & Gray represented Prilenia Therapeutics in the transaction. Prilenia Therapeutics (Prilenia), a biopharmaceutical company, announced a licensing agreement with Ferrer Internacional under which Ferrer would...
Sanofi’s $1.9 Billion Acquisition of Dren Bio’s Bispecific Antibody-Based Program
Ropes & Gray represented Sanofi in the transaction. Sanofi announced an agreement to acquire Dren Bio’s deep B-cell depleter program, DR-0201. The targeted bispecific myeloid cell...
Black Diamond Therapeutics’ Global Licensing Deal with Servier
Ropes & Gray represented Black Diamond Therapeutics in the transaction. Black Diamond Therapeutics (Nasdaq: BDTX) announced a global licensing agreement with French pharmaceutical company Servier for...
Atavistik Bio’s Research Collaboration with Pfizer
Ropes & Gray advised Atavistik Bio on the transaction. Atavistik Bio announced a research collaboration with Pfizer (NYSE: PFE) to accelerate discovery of novel precision allosteric...